VYNE Therapeutics (VYNE) Current Leases (2019 - 2025)
VYNE Therapeutics' Current Leases history spans 7 years, with the latest figure at $25000.0 for Q2 2025.
- For Q2 2025, Current Leases fell 79.17% year-over-year to $25000.0; the TTM value through Jun 2025 reached $25000.0, down 79.17%, while the annual FY2024 figure was $99000.0, 13.91% down from the prior year.
- Current Leases reached $25000.0 in Q2 2025 per VYNE's latest filing, down from $63000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $647000.0 in Q1 2021 to a low of $25000.0 in Q2 2025.
- Average Current Leases over 5 years is $193615.4, with a median of $117000.0 recorded in 2022.
- Peak YoY movement for Current Leases: plummeted 92.86% in 2022, then decreased 13.91% in 2024.
- A 5-year view of Current Leases shows it stood at $349000.0 in 2021, then crashed by 91.12% to $31000.0 in 2022, then surged by 270.97% to $115000.0 in 2023, then decreased by 13.91% to $99000.0 in 2024, then crashed by 74.75% to $25000.0 in 2025.
- Per Business Quant, the three most recent readings for VYNE's Current Leases are $25000.0 (Q2 2025), $63000.0 (Q1 2025), and $99000.0 (Q4 2024).